PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies

Duhoux, Francois P.; Ameye, Geneviève; Montano‐Almendras, Carmen P.; Bahloula, Khadija; Mozziconacci, Marie J.; Laibe, Sophy; Wlodarska, Iwona; Michaux, Lucienne; Talmant, Pascaline; Richebourg, Steven; Lippert, Eric; Speleman, Frank; Herens, Christian; Struski, Stéphanie; Raynaud, Sophie; Auger, Nathalie; Nadal, Nathalie; Rack, Katrina; Mugneret, Francine; Tigaud, Isabelle; Lafage, Marina; Taviaux, Sylvie; Roche‐Lestienne, Catherine; Latinne, Dominique; Libouton, Jeanne M.; Demoulin, Jean‐Baptiste; Poirel, Hélène A.; on behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH) and of the Belgian Cytogenetic Group for Haematology and Oncology (BCG‐HO)

doi:10.1111/j.1365-2141.2011.08918.x

Cited by 56

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies

Duhoux, Francois P., Ameye, Geneviève, Montano‐Almendras, Carmen P., Bahloula, Khadija, Mozziconacci, Marie J., Laibe, Sophy, Wlodarska, Iwona, Michaux, Lucienne, Talmant, Pascaline, Richebourg, Steven, Lippert, Eric, Speleman, Frank, Herens, Christian, Struski, Stéphanie, Raynaud, Sophie, Auger, Nathalie, Nadal, Nathalie, Rack, Katrina, Mugneret, Francine, Tigaud, Isabelle, Lafage, Marina, Taviaux, Sylvie, Roche‐Lestienne, Catherine, Latinne, Dominique, Libouton, Jeanne M., Demoulin, Jean‐Baptiste, Poirel, Hélène A., on behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH) and of the Belgian Cytogenetic Group for Haematology and Oncology (BCG‐HO)·2012·British Journal of Haematology

DOI 10.1111/j.1365-2141.2011.08918.x

Open this paper in CoChat — free account

Abstract

Summary: The PRDM16 (1p36) gene is rearranged in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) with t(1;3)(p36;q21), sharing characteristics with AML and MDS with MECOM (3q26.2) translocations. We used fluorescence in situ hybridization to study 39 haematological malignancies with translocations involving PRDM16 to assess the precise breakpoint on 1p36 and the identity of the partner locus. Reverse‐transcription polymerase chain reaction (PCR) was performed in selected cases in order to confirm the partner locus. PRDM16 expression studies were performed on bone marrow samples of patients, normal controls and CD34 + cells using TaqMan real‐time quantitative PCR. PRDM16 was rearranged with the RPN1 (3q21) locus in 30 cases and with other loci in nine cases. The diagnosis was AML or MDS in most cases, except for two cases of lymphoid proliferation. We identified novel translocation partners of PRDM16 , including the transcription factors ETV6 and IKZF1 . Translocations involving PRDM16 lead to its overexpression irrespective of the consequence of the rearrangement (fusion gene or promoter swap). Survival data suggest that patients with AML/MDS and PRDM16 translocations have a poor prognosis despite a simple karyotype and a median age of 65 years. There seems to be an over‐representation of late‐onset therapy‐related myeloid malignancies.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2011.08918.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PRDM16 controls a brown fat/skeletal muscle switch
Seale, P., Bjork, B., Yang, W., Kajimura, S., Chin, S., Kuang, S., Scimè, A., Devarakonda, S., Conroe, H. M., Erdjument-Bromage, H., et al. (2008) · Nature · doi:10.1038/nature07182 · Cited by 2,347 · cited 1×
“PRDM16 also plays a physiological role in tissue development (Warner et al, 2007; Seale et al, 2008; Kajimura et al, 2009; Bjork et al, 2010; Horn et al, 2011), a characteristic shared by many oncogenes.”
Background
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Initiation of myoblast to brown fat switch by a PRDM16–C/EBP-β transcriptional complex
Kajimura, S., Seale, P., Kubota, K., Lunsford, E., Frangioni, J. V., Gygi, S. P., & Spiegelman, B. M. (2009) · Nature · doi:10.1038/nature08262 · Cited by 703

Show all 3 references

Research works printed but not linked: 50

10.1182/blood-2010-08-300145 · DOI
10.1016/j.exphem.2003.08.003 · DOI
10.1038/onc.2009.381 · DOI
10.1038/sj.leu.2403136 · DOI
Bene M.C., 1995, Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL), Leukemia, 9, 1783
10.1038/sj.leu.2404529 · DOI
10.1093/hmg/ddp543 · DOI
Bloomfield C.D., 1985, t(1;3)(p36;q21) in acute nonlymphocytic leukemia: a new cytogenetic‐clinicopathologic association, Blood, 66, 1409, 10.1182/blood.V66.6.1409.1409 · DOI
10.1016/j.semcancer.2005.01.008 · DOI
10.1200/JCO.2008.16.0259 · DOI
10.1038/ncb2101 · DOI
10.1073/pnas.0806712105 · DOI
10.1002/gcc.20611 · DOI
10.1182/blood-2005-03-1113 · DOI
10.1371/journal.pone.0026311 · DOI
10.1002/gcc.20370 · DOI
10.1016/j.acthis.2009.09.006 · DOI
10.1182/blood.V95.8.2719 · DOI
International Standing Committee on Human Cytogenetic Nomenclature, 2009, ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009)
Jiang G.L., 2000, The yin‐yang of PR‐domain family genes in tumorigenesis, Histology and Histopathology, 15, 109
10.1016/j.jhep.2007.12.020 · DOI
10.1016/j.pharmthera.2005.03.008 · DOI
10.1038/sj.onc.1206923 · DOI
10.1006/meth.2001.1262 · DOI · Paper page
10.1200/JCO.2010.29.2771 · DOI
10.1186/1471-2407-4-45 · DOI
10.1038/leu.2010.13 · DOI
10.1182/blood.V96.9.3209 · DOI
Moir D.J., 1984, A new translocation, t(1;3) (p36;q21), in myelodysplastic disorders, Blood, 64, 553, 10.1182/blood.V64.2.553.553 · DOI
10.1073/pnas.89.9.3937 · DOI
10.1038/nature05690 · DOI
10.1038/nature06866 · DOI · Paper page
10.1182/blood-2002-12-3944 · DOI
10.1073/pnas.91.9.4004 · DOI
10.1038/sj.onc.1206867 · DOI
10.1182/blood-2007-07-102533 · DOI
10.1002/gcc.20241 · DOI
10.1016/S0968-0004(02)02141-2 · DOI
10.1002/(SICI)1098-2264(200003)27:3<229::AID-GCC2>3.0.CO;2-0 · DOI
Shing D.C., 2007, Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice, Journal of Clinical Investigation, 117, 3696
10.1038/sj.leu.2404210 · DOI
10.1016/j.bcmd.2007.11.004 · DOI
Swerdlow S.H., 2008, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
10.1074/jbc.M808989200 · DOI
10.1038/leu.2010.69 · DOI
10.1016/j.bbamcr.2007.03.016 · DOI
10.1016/j.leukres.2005.07.002 · DOI
10.1002/gcc.10176 · DOI
10.1182/blood-2003-07-2482 · DOI
10.1074/jbc.M109.056739 · DOI

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
Duncan, C. N., Bledsoe, J. R., Grzywacz, B., Beckman, A., Bonner, M., Eichler, F. S., Kühl, J.-S., Harris, M. H., Slauson, S., Colvin, R. A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405541 · Cited by 164
Digging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84
“Other HMTs known to be involved in MDS and AML include the PR domain zinc finger (PRDM) proteins PRDM3 (EVI1), which maps to 3q26, and PRDM16 (MEL1), which maps to 1q36 (Duhoux et al., 2012; Mochizuki et al., 2000; Trubia et al., 2006).”
Background

See all 56

Authors: Duhoux, F. P., Ameye, G., Montano‐Almendras, C. P., Bahloula, K., Mozziconacci, M. J., Laibe, S., Wlodarska, I., Michaux, L., Talmant, P., Richebourg, S., Lippert, E., Speleman, F., Herens, C., Struski, S., Raynaud, S., Auger, N., Nadal, N., Rack, K., Mugneret, F., Tigaud, I., Lafage, M., Taviaux, S., Roche‐Lestienne, C., Latinne, D., Libouton, J. M., Demoulin, J., Poirel, H. A., & on behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH) and of the Belgian Cytogenetic Group for Haematology and Oncology (BCG‐HO)
Venue: British Journal of Haematology
Publisher: Wiley
Published: 2011-11-03
Volume: 156
Issue: 1
Pages: 76-88
ISSN: 0007-1048
1365-2141
DOI: 10.1111/j.1365-2141.2011.08918.x
Cited by: 56
References: 3
Language: en
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page: CoChat. (2026). Citation check: PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. https://app.cochat.ai/papers/10.1111/j.1365-2141.2011.08918.x
The paper: Duhoux, F. P., Ameye, G., Montano‐Almendras, C. P., Bahloula, K., Mozziconacci, M. J., Laibe, S., Wlodarska, I., Michaux, L., Talmant, P., Richebourg, S., Lippert, E., Speleman, F., Herens, C., Struski, S., Raynaud, S., Auger, N., Nadal, N., Rack, K., Mugneret, F., . . . on behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH) and of the Belgian Cytogenetic Group for Haematology and Oncology (BCG‐HO). (2012). PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2011.08918.x

PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks

How to cite